Although, osimertinib can induce PD-L1 protein degradation and reduce PD-L1 mRNA expression in vitro, to date, the existing clinical data regarding PD-L1 association with osimertinib in EGFR-mutant NSCLC patients is contradictory. This evidence concerns the gene EGFR and non-small cell lung carcinoma.